Storia in 1 fonti

Cancer, immune drugmakers dominate VC funding so far in 2026

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

Raccontata da

biopharmadive.com

Timeline cronologica

lunedì 6 luglio 2026·biopharmadive.com
Cancer, immune drugmakers dominate VC funding so far in 2026
Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.